Market Overview
The worldwide demand for erythropoietin drugs also referred
as hematopoietic drugs is expected to remain strong in the forthcoming years.
Market Research Future (MRFR) reports that the global erythropoietin drug
market will post a above-average CAGR between 2017 and 2023. The outlook
remains positive for the global erythropoietin drug market for the medium
terms.
Erythropoietin drug are used for treating a wide range of
disorders, which include AIDS, chronic renal diseases, anaemia, cancer, among
others. Increased prevalence of such diseases is boosting the sales of
erythropoietin. Over the years, tremendous investment has been made in research
& development programs focused on drug discovery, which has also influenced
the market growth to certain extent. Several
new erythropoietin drug combinations have come up in recent years. Introduction
of new drug combinations is allowing to drug makers to cater to wider pool of
patients.
Rising awareness among patients and increased focus on
improving healthcare services in the developing countries is likely to open new
growth avenues for market players in near future. On the other hand, most of
the erythropoietin drug available are highly priced, which makes their
penetration in price sensitive markets difficult. This is viewed as a major
market constraint. Patient expiry and introduction of generic variants may provide
an impetus to drug penetration. Focus is also shifting on developing
alternative drugs formulations.
Competitive
Landscape
Amgen (US), Teva
Pharmaceutical Industries Ltd. (Israel), Emcure Pharmaceuticals (India),
Hospira (US), LG Life Sciences Ltd. (Korea), Kyowa Hakko Kirin, Boehringer
Ingelheim (US), Intas Pharmaceuticals (India), Hoffmann-La Roche (Switzerland),
Johnson & Johnson (US), Celltrion, Inc. (South Korea), 3SBio, Biocon
(India), BIOSIDUS (Argentina), and Dahua Pharmaceutical (China).
·
Reportedly, well before any other country, China
approves a new anaemia drug “Roxadustat” from FibroGen and AstraZeneca.
Roxadustat supports a novel oral anaemia treatment known as hypoxia-inducible
factor prolyl hydroxylase inhibitor. The drug is viewed as a convenient
alternative to erythropoietin or EPO.
·
AstraZeneca has recently partnered with UK-based
artificial intelligence specialist BenevolentAI. The partnership will allow
AstraZeneca to leverage machine learning and AI for drug discovery projects focusing
on idiopathic pulmonary fibrosis (IPF) and chronic kidney disease (CKD).
Segmental Overview
MRFR’s report includes a thorough segmental analysis of the
global erythropoietin drug market based on product type, application and end
user.
On the basis of product type, the market has been segmented
into second generation formulation, first generation formulation and
biosimilars. On the basis of application, the market has been segmented into
renal diseases, HIV, oncology and other. On the basis of end user, the market
has been segmented into pharmacy and hospital.
Access Report Details @ https://www.marketresearchfuture.com/reports/erythropoietin-drug-market-1360
No comments:
Post a Comment